Chemotherapy in the definitive management of oral cancers: Where do we stand today?

Oral Oncol. 2020 Mar:102:104584. doi: 10.1016/j.oraloncology.2020.104584. Epub 2020 Feb 4.

Abstract

The treatment of locally advanced oral cavity cancer is often multimodal, involving surgical resection, radiotherapy (RT), and chemotherapy. Systemic therapy is the mainstay of treatment for recurrent/metastatic disease. While the concurrent use of cisplatin with post-operative RT is well established in patients with high risk features of extranodal extension and/or positive surgical margins following resection, the role of chemotherapy in other curative settings is not clear. Studies reporting success of induction chemotherapy or definitive chemoradiotherapy in absence of primary resection include all anatomic sites of head and neck cancer, and oral cavity cancer subset is rarely reported as a separate analysis, thus limiting the interpretation of results. This article will focus on the use of systemic therapy for locoregionally advanced oral cavity cancer.

Keywords: Adjuvant therapy; Chemotherapy; Cisplatin; Head and neck cancer; Oral cavity cancer; Squamous cell carcinoma; Systemic therapy.

MeSH terms

  • Chemoradiotherapy / methods
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Humans
  • Induction Chemotherapy / methods
  • Mouth Neoplasms / drug therapy*
  • Mouth Neoplasms / pathology
  • Mouth Neoplasms / therapy
  • Postoperative Care
  • Radiation-Sensitizing Agents / administration & dosage
  • Radiation-Sensitizing Agents / adverse effects

Substances

  • Radiation-Sensitizing Agents
  • Cisplatin